Whole Exome Sequencing Market Size & Share, by Product (Systems, Kits, Services); Technology (Sequencing by Synthesis, ION Semiconductor Sequencing); Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Agriculture & Animal Research); End-user (Hospitals, Clinics, Research Centers, Academic & Government Institutes, Pharmaceutical & Biotechnology Companies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 4794
Published Date: Apr 06, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Whole Exome Sequencing Landscape

Illumina, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Bio-Rad Laboratories Inc.
Ambry Genetics
Eurofins Discovery
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
Agilent Technologies Inc.
BGI Group
Macrogen Inc.
Azenta US Inc.

Browse Key Market Insights with Data Illustration:

Whole Exome Sequencing Market Size & Share | Growth Trends 2035

In the News

The first blood virological profile of the Chinese population was created in October 2022 by BGI Group, Ruijin Hospital, and Shanghai Jiao Tong University Institute of Translational Medicine using BGI's DNBSEQ sequencing platform. This analysis involved a thorough examination of non-human genetic sequences in the whole genome sequencing (WGS) data of about 10,584 individuals from the China Metabolic Analysis Program (ChinaMAP). The findings, which were published in the journal Cell Discovery, serve as a resource for viral infection epidemiology and prevention.
The SEQuoia RiboDepletion Kit, which increases test efficiency by removing pointless ribosomal RNA (rRNA) fragments from an RNA-Seq library, has been introduced by Bio-Rad Laboratories, Inc., a world leader in life science research and clinical diagnostic products.

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are growing prevalence of rare disease, an increase in funding for genomics research, reduction in cost of sequencing, and others.

The market size of whole exome sequencing is anticipated to attain a CAGR of 25.00% over the forecast period, i.e., 2023-2035.

Lack of skilled professional, whole exome sequencing ethical & legal issue, and growing demand for WGS are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Illumina, Inc., Bio-Rad Laboratories Inc., Ambry Genetics, Eurofins Discovery, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, technology, application, end-user and by region.

The services segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Companies Dominating the Whole Exome Sequencing Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the whole exome sequencing market?

What would be the CAGR of whole exome sequencing market over the forecast period?

What are the challenges affecting the whole exome sequencing market growth?

Which region will provide more business opportunities for growth of whole exome sequencing market in future?

Who are the major players dominating the whole exome sequencing market?

How are the company profiles selected?

What are the segments in the whole exome sequencing market?

Which segment captures the largest market size in the product segment in the whole exome sequencing market?